These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 24580738)

  • 1. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
    Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
    Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
    Eckmann C; Nathwani D; Lawson W; Corman S; Solem C; Stephens J; Macahilig C; Li J; Charbonneau C; Baillon-Plot N; Haider S
    Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S33-9. PubMed ID: 26198370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the place of linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia and complicated skin and soft tissue infections in Europe?
    Dumitrescu O; Lina G
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():1-2. PubMed ID: 24580737
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
    Bounthavong M; Hsu DI; Okamoto MP
    Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of linezolid in the treatment of complicated skin and soft tissue infections.
    Peppard WJ; Weigelt JA
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
    Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
    Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Napolitano LM
    Surg Infect (Larchmt); 2008; 9 Suppl 1():s17-27. PubMed ID: 18844471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.